Definium Therapeutics, Inc. (DFTX) Investor Relations Documents
Definium Therapeutics, Inc. (DFTX) investor relations documents from the company's IR site: 2 presentations, 23 press releases; latest deck 2026-05-18. Read in-app with summaries. First-party data.
View Latest Corporate Presentation: Definium Therapeutics is a CNS-focused drug developer with $373.4M in cash, targeting GAD and MDD with its lead candidate, DT120 ODT, in Phase 3 trials.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-12 | Press release | Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety D |
| 2026-08-06 | Press release | Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights |
| 2026-08-03 | Press release | Definium Therapeutics Announces New Employee Inducement Grants |
| 2026-07-30 | Press release | Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-20 | Press release | Definium Therapeutics Announces New Employee Inducement Grants |
| 2026-07-06 | Press release | Definium Therapeutics Announces New Employee Inducement Grants |
| 2026-06-25 | Press release | Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Un |
| 2026-06-21 | Press release | Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 |
| 2026-06-15 | Press release | Definium Therapeutics Announces New Employee Inducement Grants |
| 2026-05-21 | Press release | Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-21 | Press release | Download as PDF |
| 2026-05-18 | Presentation | View Latest Corporate Presentation |
| 2026-05-12 | Press release | Download as PDF |
| 2026-05-07 | Press release | PDF |
| 2026-04-30 | Press release | Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-22 | Presentation | Investor & Analyst Day April 2026 |
| 2026-02-26 | Press release | PDF |
| 2026-02-19 | Press release | Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 |
| 2026-01-13 | Press release | Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026 |
| Press release | Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering |
| Press release | Definium Therapeutics, Inc. Announces Proposed Public Offering |
| Press release | Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet |
| Press release | MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readout |
| Press release | Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates |
| Press release | Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights |
DFTX overview · DFTX earnings · DFTX financials · DFTX KPIs · DFTX ownership · DFTX peers · DFTX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.